Nonproprietary names adopted in 2009 for antineoplasic compounds:

recombinant MAGE-A3 antigen-specific cancer immunotherapeutic GSK1203486A: non-proprietary name is Astuprotimut-R

RTA 401, CDDO: non-proprietary name is Bardoxolone;

SGN-35, cAC10-vcMMAE: non-proprietary name is Brentuximab vedotin;

SCH 727965: non-proprietary name is Dinaciclib;

CP-4055: non-proprietary name is Elacytarabine;

GSK1363089G: non-proprietary name is Foretinib;

GC1008: non-proprietary name is Fresolimumab;

CR011, CR011-vcMMAE: non-proprietary name is Glembatumumab;

ADgv EGR.TNF.11D: non-proprietary name is Golnerminogene pradenovec;

V09AB03: non-proprietary name is Ioflupane I 123;

ABT-869: non-proprietary name is Linifanib;

LY2523355; KF89617: non-proprietary name is Litronesib;

NPI-0052: non- proprietary name is Marizomib;

MGCD0103: non-proprietary name is Mocetinostat;

GSK1841157, HuMax-CD20, 2F2: non-proprietary name is Ofatumumab;

BBR 2778: non-proprietary name is Pixantrone dimaleate;

NPI-2358: non-proprietary name is Plinabulin;

AP23573, MK-8669: non-proprietary name is Ridaforolimus;

PF-04948568, CDX-110: non-proprietary name is Rindopepimut;

AZD0530: non-proprietary name is Saracatinib;

AZD0530 difumarate: non-proprietary name is Saracatinib difumarate;

ACE-011: non-proprietary name is Sotatercept;

GMX1777; EB1627: non-proprietary name is Teglarinad chloride;

SN2310: non-proprietary name is Tenifatecan;

AV-951: non-proprietary name is Tivozanib

ARRY-334543: non-proprietary name is Varlitinib;

AR00334543, ARRY-334543, ARRY-543: non-proprietary name is Varlitinib
tosylate;

MMAE, monomethyl auristatin E: non-proprietary name is Vedotin;

ABT-888: non-proprietary name is Veliparib;

hPAM4-DOTA, IMMU-107, 90hY-PAM4: non-proprietary name is Yttrium Y 90
clivatuzumab tetraxetan;

HuMax-EGFr, 2F8: non-proprietary name is Zalutumumab